Select Medical Holdings (SEM) Cost of Revenue (2018 - 2026)

Select Medical Holdings has disclosed Cost of Revenue across 9 years of filings, most recently posting $1.2 billion for Q1 2026.

• In Q1 2026, Cost of Revenue rose 6.26% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $4.9 billion (up 6.33% YoY), while the FY2025 annual figure was $4.8 billion, up 5.93% from the prior year.
• Cost of Revenue steadied at $1.2 billion in Q1 2026, from $1.3 billion in the prior quarter.
• Over the last five years, Cost of Revenue for SEM reached as high as $1.4 billion in Q1 2022 and fell as low as $16.3 million in Q4 2022.
• The 5-year median for Cost of Revenue is $1.2 billion (2025), against an average of $1.1 billion.
• Annual changes were most pronounced in 2022 — Cost of Revenue plunged 98.84% — and 2023, when it surged 6485.7%.
• A 5-year view of Cost of Revenue shows it stood at $16.3 million in 2022, then surged by 6485.7% to $1.1 billion in 2023, then gained by 9.41% to $1.2 billion in 2024, then climbed by 6.44% to $1.3 billion in 2025, then dropped by 0.38% to $1.2 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1.2 billion, $1.3 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.